

AN 2003-221653 [21] WPIX

DNC C2003-056420

TI Agents for e.g. treating and preventing malignant tumors inhibiting bone metastasis and relieving pain due to malignant tumors, comprise cyclic peptides having endothelin antagonist activity.

DC B03 B04

IN NAITO, K

PA (TAKE) TAKEDA CHEM IND LTD

CYC 99

PI WO 2003006041 A1 20030123 (200321)* JA 60<--

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

JP 2003089653 A 20030328 (200331) 22

AU 2002318669 A1 20030129 (200452)

ADT WO 2003006041 A1 WO 2002-JP7046 20020711; JP 2003089653 A JP 2002-202564
20020711; AU 2002318669 A1 AU 2002-318669 20020711

FDT AU 2002318669 A1 Based on WO 2003006041

PRAI JP 2001-212303 20010712

AN 2003-221653 [21] WPIX

AB WO2003006041 A UPAB: 20030328

NOVELTY - Agents for treating and preventing malignant tumors comprise a cyclic peptide having endothelin antagonist activity, their salts and prodrugs are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for an agent for inhibiting bone metastasis and an agent for relieving pain due to malignant tumors comprising a cyclic peptide having endothelin antagonist activity or its salt or prodrug.

ACTIVITY - Cytostatic; Analgesic; Osteopathic.

Tests using LNCaP C4-2 and MCF-7, ZR-75-1 cancers cells are described but no results are given.

MECHANISM OF ACTION - Endothelin-Antagonist.

USE - The agents are used as endothelin antagonists for treating and preventing malignant tumors, inhibiting bone metastasis and relieving pain due to malignant tumors.
Dwg.0/0